These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 10836339)
41. Endothelin receptor antagonists in a beagle model of pulmonary hypertension: contribution to possible potential therapy? Okada M; Yamashita C; Okada M; Okada K J Am Coll Cardiol; 1995 Apr; 25(5):1213-7. PubMed ID: 7897136 [TBL] [Abstract][Full Text] [Related]
42. Pulmonary hypertension secondary to left ventricular dysfunction: the role of nitric oxide and endothelin-1 in the control of pulmonary vascular tone. Deuchar GA; Docherty A; MacLean MR; Hicks MN Br J Pharmacol; 2002 Feb; 135(4):1060-8. PubMed ID: 11861335 [TBL] [Abstract][Full Text] [Related]
43. Circulatory responses to endothelin-1 and nitric oxide with special reference to endotoxin shock and nitric oxide inhalation. Weitzberg E Acta Physiol Scand Suppl; 1993; 611():1-72. PubMed ID: 8379340 [TBL] [Abstract][Full Text] [Related]
44. Starling resistor effects on pulmonary artery occlusion pressure in endotoxin shock provide inaccuracies in left ventricular compliance assessments. Fang K; Krahmer RL; Rypins EB; Law WR Crit Care Med; 1996 Oct; 24(10):1618-25. PubMed ID: 8874296 [TBL] [Abstract][Full Text] [Related]
50. Selective or nonselective endothelin antagonists in porcine hypoxic pulmonary hypertension? Franco-Cereceda A; Holm P J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S447-52. PubMed ID: 9595509 [TBL] [Abstract][Full Text] [Related]
51. The hemodynamic effects of endothelin receptor antagonism during a venous air infusion in dogs. Tanus-Santos JE; Gordo WM; Udelsmann A; Moreno H Anesth Analg; 2000 Jan; 90(1):102-6. PubMed ID: 10624986 [TBL] [Abstract][Full Text] [Related]
52. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Ooi H; Colucci WS; Givertz MM Circulation; 2002 Sep; 106(13):1618-21. PubMed ID: 12270852 [TBL] [Abstract][Full Text] [Related]
53. No redistribution of lung blood flow by inhaled nitric oxide in endotoxemic piglets pretreated with an endothelin receptor antagonist. Trachsel S; Hambraeus-Jonzon K; Bergquist M; Martijn C; Chen L; Hedenstierna G J Appl Physiol (1985); 2015 Mar; 118(6):768-75. PubMed ID: 25549764 [TBL] [Abstract][Full Text] [Related]
54. Post-cardiopulmonary bypass pulmonary hypertension in lambs with increased pulmonary blood flow. A role for endothelin 1. Reddy VM; Hendricks-Munoz KD; Rajasinghe HA; Petrossian E; Hanley FL; Fineman JR Circulation; 1997 Feb; 95(4):1054-61. PubMed ID: 9054770 [TBL] [Abstract][Full Text] [Related]
55. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956 [TBL] [Abstract][Full Text] [Related]
56. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350 [TBL] [Abstract][Full Text] [Related]
57. Dynamic study of nitric oxide and endothelin-1 during endotoxin shock and effects of their antagonists on hemodynamics. Wang S; Hao G; Shen X; Jing D Chin Med J (Engl); 1998 Mar; 111(3):242-7. PubMed ID: 10374426 [TBL] [Abstract][Full Text] [Related]
58. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. Chen SJ; Chen YF; Opgenorth TJ; Wessale JL; Meng QC; Durand J; DiCarlo VS; Oparil S J Cardiovasc Pharmacol; 1997 Jun; 29(6):713-25. PubMed ID: 9234651 [TBL] [Abstract][Full Text] [Related]